CTLA4 and cancer: Immune checkpoint inhibitors (CPIs) that target the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway have demonstrated remarkable efficacy across a wide variety of cancer types (1).